The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
NCT05085561
Brain Diseases, Cardiovascular Abnormalities
Phoenix, Arizona, United States
View Trial DetailsNCT Number: NCT01764529
Cerebral cavernous malformations (CCMs) are clusters of abnormal blood vessels in the brain and spine. CCMs can bleed and cause strokes, seizures, and headaches. CCMs are often caused by an inherited gene mutation (alteration) in one of three CCM genes (CCM1, CCM2, or CCM3). There is a wide range of disease severity even among family members with this disease, though the natural history has not been clearly described for this particular population.
This study will continue to enroll and follow participants with familial CCM to identify factors that influence CCM disease severity and progression, focusing on barriers to clinical trial preparedness. Our long-term goal is to identify measurable outcomes and robust biomarkers that will help select high-risk patients and help monitor drug response in future clinical trials.
The specific goals of this study are to:
* Identify factors that influence lesion progression to symptomatic hemorrhage and other outcomes, including quality of life; * Investigate the role of the gut microbiome and lesion burden in CCM disease, and * Identify blood biomarkers predictive of CCM disease severity and progression for clinical trials.
Looking for future studies?
Notify MeAll sexes
Observational
Barrow Neurological Institute, Phoenix, Arizona, United States
This study is one of three projects participating in the Brain Vascular Malformation Consortium (BVMC) funded by the Office of Rare Diseases Research, which is part of the National Center for Advancing Translational Sciences (NCATS), and the National Institute of Neurological Disorders and Stroke (NINDS).
The CCM project is a cross-sectional and longitudinal study of familial CCM patients. The study is currently in the third 5-year cycle. During the first 5 year cycle (BVMC1), the CCM project was focused on recruiting CCM1 cases with the common Hispanic mutation (CHM). In the second 5-year cycle (BVMC2), we expanded recruitment to include not only CCM1-CHM cases, but also other CCM familial patients and mutation carriers. In the third 5-year cycle (BVMC3), we will continue to recruit familial CCM cases and expand to additional recruitment sites.
We collect clinical, genetic, imaging, treatment, and outcome data in participants, and follow enrolled participants over time to understand the natural history of this disease.
For new study participants, you will be asked to:
Eligible cases include those with a known genetic mutation in one of the three CCM genes or those that meet 2 of 3 following clinical criteria:
Exclusion criteria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline
The number of lesions (or cavernous angiomas) located in the brain will be counted by a neuroradiologist and by an automated algorithm developed as part of this project.
Time frame: Baseline and annual assessment
Symptomatic hemorrhage is defined as diagnostic evidence of new lesional bleeding or hemorrhagic growth, in association with directly attributable symptoms. Rate of symptomatic hemorrhage and the factors that influence hemorrhage rates will be assessed.
Time frame: Baseline, Follow up MRI
The number of lesions (or cavernous angiomas) counted on the baseline MRI will be compared to the number of lesions observed in follow up MRIs.
Time frame: Baseline and annual assessment
The modified Rankin score will be assessed at baseline and at approximately one year intervals while remaining in study
Time frame: Baseline and annual assessment
Standardized patient reported outcome measurement tools to assess pain, fatigue, physical function, emotional distress, and social participation.
University of California, San Francisco
Other
Modifiers of Disease Severity and Progression in Cerebral Cavernous Malformations
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05085561
Brain Diseases, Cardiovascular Abnormalities
Phoenix, Arizona, United States
View Trial DetailsNCT02603328
Brain Diseases, Cardiovascular Abnormalities
Chicago, Illinois, United States
View Trial DetailsNCT03652181
Brain Diseases, CCM
Chicago, Illinois, United States
View Trial DetailsNCT03589014
Brain Diseases, Cardiovascular Abnormalities
San Giovanni Rotondo, FG, Italy
View Trial Details